Evinova, a new health-tech business launched by AstraZeneca, will utilize the company’s expertise in clinical trial design and study delivery. The venture aims to provide solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.

Evinova’s offerings include advanced data collection methods and machine learning algorithms to support teams in designing their studies. This will help reduce the time and cost of developing new medicines, bring care closer to home for patients, and ease the burden on healthcare systems. The company has announced partnerships with Parexel and Fortrea to expand the reach of its digital health solutions to a wider customer base.

AstraZeneca’s Chief Executive, Pascal Soriot, expressed his confidence in Evinova’s potential to make a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The digital health market is projected to grow significantly in the coming years, reaching over $900 billion by 2032.

For more information about Evinova and its offerings, please contact Michael Susin at michael.susin@wsj.com.